Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

The drug combination was safe and showed promise in treating advanced tumors.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Topical ruxolitinib cream may help treat frontal fibrosing alopecia.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Pexidartinib often causes liver issues and fatigue, especially in women.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.

Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.